CD274 and non-small cell lung carcinoma: This study found that elderly patients with advanced NSCLC in the PD-L1 high-expression subgroup could benefit from ICIs combined with anti-angiogenic drugs, and the IA group showed a safety advantage due to the lower proportion of combined chemotherapy compared to the NIA group.